McKesson

McKesson

Yahoo Finance • 2 days ago

Option Care Health (OPCH) Stock May Be Undervalued Despite The $5.8 Billion Buyout

Option Care Health shares have jumped into focus after a sharp move higher and a US$5.8b buyout agreement, which raises a straightforward question for investors who care about valuation. Does the current price around the deal level make se... Full story

Yahoo Finance • 3 days ago

How AI Adoption Could Supercharge McKesson (MCK)

Suncoast Equity Management, an SEC-registered Investment Advisory (RIA), released its Q3 2026 investor letter for "U.S. Equity Large Cap Select Growth Strategy." The letter can be downloaded here. The strategy advanced 4.2% after fees in Q... Full story

Yahoo Finance • 5 days ago

Sector Update: Healthcare Stocks Mixed Late Afternoon

Healthcare stocks were mixed late Tuesday afternoon, with the NYSE Healthcare Index up 0.2% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 5 days ago

McKesson, CD&R to Buy Option Care Health in $5.8 Billion Deal

Drug distributor McKesson (MCK) and private investment firm Clayton Dubilier & Rice agreed to acquir PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 8 days ago

3 Cash Rich US Stocks Investors Are Watching As Bond Yields Stay High

Bond yields have surged to levels not seen in decades, mortgage rates now sit above 7% and big institutional players are pulling back from Treasuries. That combination is reshaping how investors think about risk, cash flow and balance shee... Full story

Yahoo Finance • 10 days ago

EPIC Rx Introduces New Wholesale Distribution Options for Member Pharmacies

New model gives member pharmacies the flexibility to select between McKesson and Morris & Dickson based on their individual business and patient needs. RICHMOND, Va., October 01, 2026--(BUSINESS WIRE)--EPIC Pharmacies, Inc. (EPIC Rx), a n... Full story

Yahoo Finance • 18 days ago

McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know

McKesson (MCK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this prescription d... Full story

Yahoo Finance • 24 days ago

1 Unpopular Stock That Deserves Some Love and 2 We Turn Down

1 Unpopular Stock That Deserves Some Love and 2 We Turn Down When Wall Street turns bearish on a stock, it's worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will l... Full story

Yahoo Finance • 25 days ago

Alluvium Raised Its McKesson (MCK) Stake as Long-Term Growth Expectations Remain Strong

Alluvium Asset Management, an asset management company, released its "Conventum – Alluvium Global Fund" second-quarter 2026 investor letter. The letter can be downloaded here. The second quarter reflected a sharp shift from geopolitical un... Full story

Yahoo Finance • 27 days ago

AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between a mature pharmaceutical giant and a speculative gene-editing pioneer requires a clear understanding of your personal risk tolerance. Do you prefer AbbVie (NYSE:ABBV) or CRISPR Therapeutics (NASDAQ:CRSP) in 2026? AbbVie is... Full story

Yahoo Finance • 27 days ago

McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal

Key Points Interested in McKesson Corporation? Here are five stocks we like better. McKesson raised its full-year EPS guidance by $0.40 to $44.20–$45.00, reflecting approximately 13%–15% growth, or 15%–17% excluding certain prior-year ite... Full story

Yahoo Finance • 27 days ago

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) requires balancing the stability of a diversified pharmaceutical giant against the high-growth, high-margin profile of a specialized biotechnology pioneer. Amge... Full story

Yahoo Finance • 30 days ago

Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Investors often face a choice between the stability of established giants and the high-stakes potential of clinical-stage innovators. Deciding between Amgen (NASDAQ:AMGN) and CRISPR Therapeutics (NASDAQ:CRSP) requires balancing immediate d... Full story

Yahoo Finance • last month

Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?

Should you bet on an established giant or a pipeline-driven innovator? This comparison examines Amgen (NASDAQ:AMGN) and Moderna (NASDAQ:MRNA) to see which stock is a better buy today. Amgen is a veteran in the drug manufacturing world, fo... Full story

Yahoo Finance • last month

Cardinal (CAH) Up 2.5% Since Last Earnings Report: Can It Continue?

It has been about a month since the last earnings report for Cardinal Health (CAH). Shares have added about 2.5% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings releas... Full story

Yahoo Finance • last month

3 Market-Beating Stocks for Long-Term Investors

3 Market-Beating Stocks for Long-Term Investors The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become... Full story

Yahoo Finance • last month

McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates

Cardinal Health Earnings: Can Perfection Get Priced In Twice? McKesson (NYSE:MCK) discussed its planned $2.25 billion acquisition of Precision Medicine Group, first-quarter operating trends and capital-allocation priorities during a prese... Full story

Yahoo Finance • last month

Reliant Infusion Names Tommy Pourmahram Chief Executive Officer

Former McKesson Oncology & Multispecialty executive joins the Shore Capital-backed specialty infusion provider to accelerate its regional and national expansion CHICAGO, September 08, 2026--(BUSINESS WIRE)--Shore Capital Partners ("Shore"... Full story

Yahoo Finance • last month

Here's How CVS Is Focusing on Aetna's Profitability Turnaround

CVS Health CVS is executing a multi-year plan to restore Aetna, its insurance business, to target margins. The strategy focuses on disciplined pricing, better medical cost management, clinical programs and operational improvements. The ben... Full story

Yahoo Finance • last month

McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy

Reuters reported that McKesson Corporation (NYSE:MCK) said it would buy privately held Precision Medicine Group in a deal valued at about $2.25 billion as part of a "years-long effort to strengthen its higher-growth businesses." McKesson... Full story